|
|
Article: Illumina Stock Sale Gets $83.6M For Diagnostics Work And More.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Illumina Inc. pulled down net proceeds of about $83.6 million through a public offering of 3.5 million shares of common stock at $25.50 per share, and aims to use the money partly to boost diagnostics work.
"You can see the direction we're going by the DeCode deal we announced [last] Monday," said Jay Flatley, president and CEO of San Diego-based Illumina. With DeCode Genetics, of Reykjavik, Iceland, Illumina plans to co-develop and commercialize DNA-based diagnostic tests in several major disease areas, including heart attack, diabetes and breast cancer.
The deal will use Illumina's platform for high-multiplex ...
Related newspaper, magazine, and journal articles:
|
|
Article: Illumina to Present at the Goldman Sachs Global Healthcare ...
Investment Weekly News;
June 27, 2009 ;
700+ words
...Illumina, Inc. (NASDAQ:ILMN) announced that ... Goldman Sachs Global Healthcare Conference in New York, New York, on June 10, 2009. The live ... Corporate/Investor Information" tab of Illumina's web site at www.illumina.com. About ...
|
|